Silicon-Containing Cationic Lipids for Biodegradable Nanoparticle Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The preparation of cationic lipid nanoparticles for active agent delivery is hindered by high costs and inefficiencies in current processes, and there is a need for biodegradable cationic lipids that facilitate effective delivery and degradation post-delivery.
Innovation Solution
Development of cationic lipids with specific chemical structures (R1, R2, R3, X, and R4) that can be prepared using less expensive and more efficient processes, allowing for the formulation of lipid nanoparticles that are biodegradable and effective in delivering active agents such as nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cationic lipids are used for nanoparticle preparation, then delivery effectiveness is achieved, but preparation cost increases and manufacturing efficiency decreases
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as the hydrocarbon chain length (R1, R2, R3 as C2-C30 hydrocarbyl groups), the linker structure (X as divalent C2-C8 alkyl), and the head group composition (R4 as NRaRb with specific alkyl substitutions). These parameter changes enable the lipids to be synthesized through more cost-effective and efficient processes while preserving their ability to form stable nanoparticles for effective drug delivery
2Reliability
If conventional cationic lipids are used, then nanoparticle formation is achieved, but biodegradability is insufficient
Solution Approach 1:
The patent introduces biodegradable characteristics by selecting specific hydrocarbyl groups (R1, R2, R3) that can be metabolized by the body, using biocompatible linkers (X as divalent C2-C8 alkyl), and incorporating amino groups (R4 as NRaRb) that can be degraded through physiological processes. These parameter changes allow the nanoparticles to degrade after delivering their therapeutic cargo, reducing long-term toxicity and improving safety profiles
Data Source
AI summary
Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.